Nykode Therapeutics AS Statistics
Total Valuation
Nykode Therapeutics AS has a market cap or net worth of NOK 2.10 billion. The enterprise value is 699.00 million.
Market Cap | 2.10B |
Enterprise Value | 699.00M |
Important Dates
The last earnings date was Wednesday, August 28, 2024.
Earnings Date | Aug 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nykode Therapeutics AS has 326.55 million shares outstanding. The number of shares has increased by 17.11% in one year.
Shares Outstanding | 326.55M |
Shares Change (YoY) | +17.11% |
Shares Change (QoQ) | +23.59% |
Owned by Insiders (%) | 16.69% |
Owned by Institutions (%) | 17.66% |
Float | 143.42M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 29.70 |
PB Ratio | 1.30 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -1.73 |
EV / Sales | 10.07 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.74 |
Financial Position
The company has a current ratio of 9.28, with a Debt / Equity ratio of 3.15.
Current Ratio | 9.28 |
Quick Ratio | 9.28 |
Debt / Equity | 3.15 |
Debt / EBITDA | n/a |
Debt / FCF | -0.05 |
Interest Coverage | -272.46 |
Financial Efficiency
Return on equity (ROE) is -25.99% and return on invested capital (ROIC) is -24.31%.
Return on Equity (ROE) | -25.99% |
Return on Assets (ROA) | -19.95% |
Return on Capital (ROIC) | -24.31% |
Revenue Per Employee | 387,918 |
Profits Per Employee | -2.26M |
Employee Count | 173 |
Asset Turnover | 0.04 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.11% in the last 52 weeks. The beta is 1.44, so Nykode Therapeutics AS's price volatility has been higher than the market average.
Beta (5Y) | 1.44 |
52-Week Price Change | -77.11% |
50-Day Moving Average | 12.43 |
200-Day Moving Average | 15.55 |
Relative Strength Index (RSI) | 26.07 |
Average Volume (20 Days) | 3,768,688 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nykode Therapeutics AS had revenue of NOK 69.44 million and -404.04 million in losses. Loss per share was -1.29.
Revenue | 69.44M |
Gross Profit | 69.44M |
Operating Income | -627.15M |
Pretax Income | -509.45M |
Net Income | -404.04M |
EBITDA | -619.58M |
EBIT | -627.15M |
Loss Per Share | -1.29 |
Balance Sheet
The company has 1.45 billion in cash and 51.00 million in debt, giving a net cash position of 1.40 billion or 4.30 per share.
Cash & Cash Equivalents | 1.45B |
Total Debt | 51.00M |
Net Cash | 1.40B |
Net Cash Per Share | 4.30 |
Equity (Book Value) | 1.62B |
Book Value Per Share | 4.96 |
Working Capital | 1.33B |
Cash Flow
In the last 12 months, operating cash flow was -931.02 million and capital expenditures -11.57 million, giving a free cash flow of -942.59 million.
Operating Cash Flow | -931.02M |
Capital Expenditures | -11.57M |
Free Cash Flow | -942.59M |
FCF Per Share | -2.89 |
Margins
Gross Margin | 100.00% |
Operating Margin | -903.19% |
Pretax Margin | -733.69% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -1,357.47% |
Dividends & Yields
Nykode Therapeutics AS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -17.11% |
Shareholder Yield | -17.11% |
Earnings Yield | -20.06% |
FCF Yield | -44.82% |
Stock Splits
The last stock split was on July 7, 2020. It was a forward split with a ratio of 5.
Last Split Date | Jul 7, 2020 |
Split Type | Forward |
Split Ratio | 5 |